Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AbbVie, accomplished, accuracy, adaptable, ahead, air, alkalization, alveoli, amidite, ancestry, antiviral, apportioned, arm, Article, Asian, ASN, ATRA, Avenue, Avidity, banking, Bellina, bifurcate, biopsy, Blueprint, bodily, Boston, Boulder, broader, bulk, Cadillac, cap, caution, Cayman, CCPA, Ciappenelli, clarification, clarity, CNS, COBRA, Cologne, composed, congenital, Connecticut, construed, corroborating, Corrupt, corrupted, COSO, cyberattack, cybersecurity, deceptive, Deloitte, denial, descent, dialogue, disagree, disaster, disposition, disregarded, dissolved, domestically, dropped, duplex, editing, EEA, elastase, electorate, engineer, escalating, espionage, ESTRELLA, exceeding, excise, exemplify, expiry, Exploratory, falsification, faster, FCPA, fight, Frank, fullest, Gilead, glycolate, gradually, hacking, heard, hepatocellular, highlighted, House, ICER, ideal, imaging, immigration, implanted, implicit, improperly, inaccurate, incentivize, indefinite, inflation, infused, inhaled, instability, instated, instilled, intact, interfering, IRC, Johnson, Jordan, leadership, leakage, leave, lessee, LLP, lump, lung, malfunction, mapped, mapping, Maryland, mathematical, Matthew, McLinn, methodology, mild, Millennium, misuse, mixed, Moda, moderate, Mogiello, nascent, necessity, nedosiran, neutrophil, newest, nighttime, noncancelable, noncurrent, nondeductible, nonlease, nonsolicitation, Nordisk, Novo, NPS, NUC, nurse, occupy, outbreak, outsource, outsourced, overproduction, oversee, oxidase, penetrate, pgRNA, pharmacoeconomic, phishing, placebo, pocket, poverty, pro, proceed, pulmonary, purport, ransomware, rata, recombinant, reconsider, redundancy, regime, relocate, remanded, remote, rental, repair, rescind, rescinded, Rob, ROU, run, scar, seasoned, Senate, Shire, software, sophisticated, specialty, spent, statistical, step, stolen, strict, subset, sudden, Swedish, symptomatic, territory, text, tightly, Touche, transmit, Trickett, uncommon, Uncontrolled, undertook, unearned, unexplained, unprecedented, unqualified, vendor, Vertex, visit, Wendler, white, wider, Wisconsin
Removed:
acute, back, Cambridgepark, capability, capacity, cardiovascular, catenin, center, chronically, compliantly, controller, cut, dedicated, discontinued, diversity, EITF, elevated, EnCoreTM, excessive, filer, flux, formal, functional, furnish, goodwill, halt, heavily, hope, hurt, hypercholesterolemia, improving, infected, inhibition, intake, linked, LNP, Minister, mutation, oncogene, Pharma, plasma, POC, positioning, predictive, prime, progressive, reconcile, region, rejection, response, restriction, robust, Sanofi, stabilized, supplied, timeframe, toxicology, transplant, tumor, unlawful
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Exhibit 4.1
- 10.29 Exhibit 10.29
- 10.30 Exhibit 10.30
- 10.31 Exhibit 10.31
- 10.32 Exhibit 10.32
- 10.33 Exhibit 10.33
- 10.46 Exhibit 10.46
- 10.47 Exhibit 10.47
- 10.48 Exhibit 10.48
- 10.52 Exhibit 10.52
- 10.53 Exhibit 10.53
- 10.54 Exhibit 10.54
- 10.55 Exhibit 10.55
- 10.56 Exhibit 10.56
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- Download Excel data file
- View Excel data file
Related press release
Associated DRNA transcripts
DRNA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements No. 333-234572 on Form S-3ASR, Nos. 333-202687, 333-214082, 333-223778, and 333-224989 on Form S-3 and in Registration Statement Nos. 333-193795, 333-210071, 333-223648, and 333-233149 on Form S-8 of our reports dated February 27, 2020, relating to the consolidated financial statements of Dicerna Pharmaceuticals, Inc. and the effectiveness of Dicerna Pharmaceuticals, Inc.'s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Dicerna Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 27, 2020